Comparing the Efficacy of Eletriptan for Migraine in Women During Menstrual and Non-Menstrual Time Periods: A Pooled Analysis of Randomized Controlled Trials
Article first published online: 29 OCT 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 54, Issue 2, pages 343–354, February 2014
How to Cite
Bhambri, R., Martin, V. T., Abdulsattar, Y., Silberstein, S., Almas, M., Chatterjee, A. and Ramos, E. (2014), Comparing the Efficacy of Eletriptan for Migraine in Women During Menstrual and Non-Menstrual Time Periods: A Pooled Analysis of Randomized Controlled Trials. Headache: The Journal of Head and Face Pain, 54: 343–354. doi: 10.1111/head.12257
Conflict of Interest: R.B., M.A., Y.A., and E.R. are paid employees of Pfizer Inc. A.C. was an employee of Pfizer at the time this study was conducted and the manuscript was drafted.
V.M. has received a grant from GSK; has acted as consultant for Nautilus Pharma, Allergan, and Zogenix; and has acted as a speaker for Allergan and Zogenix.
S.S. is on the advisory panel of and receives honoraria from Allergan, Capnia, Iroko Pharmaceuticals, Lilly, MAP, Medtronic, Neuralieve, NINDS, NuPathe, Pfizer, and St. Jude Medical; serves as a consultant for and receives honoraria from Alderbio, Amgen, Electrocore, Opti-Nose, and Zogenix; employer receives research support from Allergan, BMS, Cumberland, ElectroCore, Lilly, Merck, Merz, Opti-Nose, St. Jude Medical, and Troy Healthcare.
Financial Support: This analysis was designed, undertaken, and funded by Pfizer Inc.
Clinical Trial Registration Number: Not applicable.
- Issue published online: 10 FEB 2014
- Article first published online: 29 OCT 2013
- Manuscript Accepted: 17 SEP 2013
- Pfizer Inc.